Cencora, Inc. (VIE:ABC)
Austria · Delayed Price · Currency is EUR | Market Cap | 54.73B +15.6% |
| Revenue (ttm) | 277.46B +7.4% |
| Net Income | 1.38B +16.4% |
| EPS | 7.10 +18.6% |
| Shares Out | n/a |
| PE Ratio | 39.54 |
| Forward PE | 18.02 |
| Dividend | 1.98 (0.72%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 6 |
| Average Volume | 5 |
| Open | 272.20 |
| Previous Close | 272.50 |
| Day's Range | 272.20 - 276.90 |
| 52-Week Range | 237.50 - 330.40 |
| Beta | n/a |
| RSI | 39.00 |
| Earnings Date | May 6, 2026 |
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, ... [Read more]
Financial Performance
In fiscal year 2025, Cencora's revenue was $321.33 billion, an increase of 9.31% compared to the previous year's $293.96 billion. Earnings were $1.55 billion, an increase of 2.99%.
Financial numbers in USD Financial StatementsNews
Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening...
Cencora to buy retina business of EyeSouth Partners for $1.1 billion
Drug distributor Cencora said on Monday it would buy the retina business of eye care network EyeSouth Partners for $1.1 billion, expanding its eye care unit.
Cencora to Expand Retina Consultants of America Through Acquisition of EyeSouth Partners' Retina Business
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the signing of a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. Upon completion of t...
Cencora Announces Financial Leadership Transition
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora ...
Cencora's animal health unit to merge with Covetrus in $3.5 billion deal
Drug distributor Cencora will merge its MWI Animal Health unit with privately held Covetrus in a deal that values MWI at $3.5 billion, the companies said on Wednesday.
Covetrus and MWI Animal Health to Merge
CONSHOHOCKEN, Pa. & PORTLAND, Maine--(BUSINESS WIRE)--Cencora (NYSE: COR) and Covetrus, a global animal health technology and services company, today announced that they have entered into a definitive...
Cencora Closes $3.0 Billion Senior Notes Offering
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, ...
Cencora Prices $500 Million 3.950% Senior Notes Due 2029, $500 Million 4.250% Senior Notes Due 2030, $500 Million 4.600% Senior Notes Due 2033, $1.0 Billion 4.900% Senior Notes Due 2036 and $500 Million 5.650% Senior Notes Due 2056
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the “2029 Notes”)...
Cencora beats quarterly profit estimates on strong demand for specialty medicines
Cencora on Wednesday beat Wall Street estimates for first-quarter profit, as the drug distributor rode the wave of sustained demand for specialty medicines and GLP-1 therapies.
Cencora Reports Fiscal 2026 First Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 first quarter ended December 31, 2025, revenue increased 5.5 percent year-over-year to $85.9 billion...
Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products
ATLANTA--(BUSINESS WIRE)--Curant Rare today announced a strategic collaboration with Cencora, a global pharmaceutical solutions organization, that aims to provide pharmaceutical companies developing r...
Cencora Elects Ellen Cooper to Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Ellen Cooper as a new independent director, effective January 20, 2026. Ms. Cooper...
Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2026 on Wednesday, February 4, 2026, prior to the ope...
Cencora to take majority control of OneOncology to expand cancer services
U.S. drug distributor Cencora said on Monday it will take majority control of cancer care network OneOncology in a deal that values the business at $7.4 billion, as it moves to expand services for com...
Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not cu...
Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain Capabilities
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced investments to enhance its third-party logistics (3PL) capabilities in the United States and Eur...
Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast
Cencora will invest over $1 billion through 2030 to expand its U.S. network, the drug distributor said on Wednesday, after forecasting adjusted profit for next year above Wall Street expectations.
Drug Distributor Cencora to Invest $1 Billion in U.S. Supply Chain
The company will open two new distribution centers and expand a third as demand surges for GLP-1s and other refrigerated medications.
Cencora Announces $1 Billion Investment to Strengthen Its U.S. Distribution Network
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced plans to invest $1 billion through 2030 to bolster and expand its pharmaceutical distribution ne...
Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Reven...
IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina ...
The Market Took a Hit. These 6 Stocks Can Sidestep the Wreckage.
Those looking to buy stocks right now should look for the ones that aren't correlated to the artificial intelligence trade.
Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2025 on Wednesday, November 5, 2025, prior to the op...
Cencora Appoints Mark Durcan as Chairman of Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, ...
Cencora raises annual profit forecast on strong demand for specialty drugs
U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped Wall Street estimates, buoyed by surging demand for specialty therapies and bl...